Cytosorbents (CTSO) Retained Earnings (2010 - 2026)

Cytosorbents has reported Retained Earnings for 17 years, with the latest figure at -$317.3 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 3.88% year-over-year to -$317.3 million; the trailing twelve-month figure through Mar 2026 stood at -$317.3 million (down 3.88% YoY), and the FY2025 full-year result was -$3.0 million, up 99.02% from the prior year.
• Retained Earnings for Q1 2026 stood at -$317.3 million, down from -$3.0 million in the prior quarter.
• The five-year high for Retained Earnings was $6.2 million in Q3 2022, with the low at -$317.3 million in Q1 2026.
• Historically, Retained Earnings has averaged -$170.2 million across 5 years, with a median of -$268.0 million in 2023.
• Annual changes were most pronounced in 2022 — Retained Earnings surged 521.21% — and 2023, when it plunged 17658.98%.
• Cytosorbents' Retained Earnings stood at $2.3 million in 2022, then plunged by 12262.56% to -$283.3 million in 2023, then decreased by 7.31% to -$304.0 million in 2024, then surged by 99.02% to -$3.0 million in 2025, then slumped by 10559.59% to -$317.3 million in 2026.
• The last three Retained Earnings figures came in at -$317.3 million (Q1 2026), -$3.0 million (Q4 2025), and -$3.8 million (Q3 2025), per Business Quant data.